It has been reported that agonists of peroxisome proliferator-activated receptor g (PPARg) inhibit proliferation of breast carcinoma cells, but the biological significance of PPARg remains undetermined in human breast carcinomas. Therefore, we immunolocalized PPARg in 238 human breast carcinoma tissues. PPARg immunoreactivity was detected in 42% of carcinomas, and was significantly associated with the status of estrogen receptor (ER) a, ERb, progesterone receptor, retinoic X receptors, p21 or p27, and negatively correlated with histological grade or cyclooxygenase-2 status. PPARg immunoreactivity was significantly associated with an improved clinical outcome of breast carcinoma patients by univariate analysis, and multivariate analysis demonstrated that PPARg immunoreactivity was an independent prognostic factor for overall survival in ERa-positive patients. We then examined possible mechanisms of modulation by PPARg on estrogenic actions in MCF-7 breast carcinoma cells. A PPARg activator, 15-deoxy-D 12,14 -prostaglandin J 2 (15d-PGJ 2 ), significantly inhibited estrogen-responsive element-dependent transactivation by estradiol in MCF-7 cells, which was blocked by addition of a PPARg antagonist GW9662. Subsequent study, employing a custom-made microarray focused on estrogenresponsive genes, revealed that mRNA expression was significantly regulated by estradiol in 49 genes, but this significance vanished on addition of 15d-PGJ 2 in 16 out of 49 (33%) genes. These findings were confirmed by real-time PCR in 11 genes. 15d-PGJ 2 significantly inhibited estrogenmediated proliferation of MCF-7 cells, and caused accumulation of p21 and p27 protein. These results suggest that PPARg is mainly expressed in well-differentiated and ER-positive breast carcinomas, and modulates estrogenic actions.
Introduction
Peroxisome proliferator-activated receptor g (PPARg) is a member of the nuclear hormone receptor superfamily, and has also been designated NR1C3 (Lemberger et al. 1996 , Schoonjans et al. 1996 . PPARg functions as a transactivation factor following heterodimerization with retinoic X receptors (RXRs), and binds to its specific response elements termed peroxisome proliferating responsive elements (PPREs) of various target genes (Mangelsdorf & Evans 1995) . of neoplastic cells (Koeffler 2003) . For instance, PPARg agonist inhibits the proliferation of human breast cancers (Elstner et al. 1998 , Mueller et al. 1998 , Yee et al. 1999 , and a phase II clinical trial using PPARg ligands has been recently performed as a novel therapy for advanced breast cancer patients (Burstein et al. 2003) .
It then becomes very important to obtain a better understanding of the clinical and/or biological roles of PPARg in breast cancer tissues in order to improve the potential clinical efficiency of PPARg ligand therapy for breast cancer patients. Mueller et al. (1998) previously demonstrated the expression of PPARg in human primary and metastatic cancers, and Wang et al. (2004) reported higher amounts of PPARg expression in breast carcinoma cells than in normal human mammary epithelial cells. However, it has been also demonstrated that PPARg expression is significantly lower in breast cancer tissues at both mRNA (Jiang et al. 2003) and protein (Watkins et al. 2004) levels than that in normal tissues. Expression of PPARg has been examined in human breast carcinomas by several groups, but little information is available on the clinicopathological features of PPARg-positive breast cancers. Therefore, the biological significance of PPARg remains largely undetermined in human breast carcinoma. In this study, we examined immunolocalization of PPARg in 238 cases of human breast carcinoma patients, and correlated these findings with various clinicopathological parameters. As the results of immunohistochemistry demonstrated a strong association between PPARg and estrogen receptor (ER) a in breast carcinomas, we also examined a possible modulation by PPARg on estrogenic actions in breast cancer cells for further characterization of PPARg in human breast carcinoma.
Materials and methods

Patients and tissues
Two hundred and thirty-eight surgical pathology specimens of invasive ductal carcinoma of the breast were retrieved from pathology archives of the Department of Surgery, Tohoku University Hospital, Sendai, Japan. Breast tissue specimens were obtained from female patients who underwent mastectomy from 1982 to 1992 with a mean age of 54.1 years (range 22-82). The patients did not receive chemotherapy or irradiation prior to surgery. Review of the charts of patients revealed that 194 patients received adjuvant chemotherapy, and 43 patients received tamoxifen therapy after surgery. The mean follow-up time was 102 months (range 2-157 months). The histological grade of each specimen was evaluated based on the method of Elston & Ellis (1991) . All specimens were fixed with 10% formalin and embedded in paraffin wax. Research protocols for this study were approved by the Ethics Committee at Tohoku University School of Medicine (approved number: 2000-142) .
Antibodies
Rabbit polyclonal antibody for PPARg was raised against a synthetic peptide corresponding to amino acids 60-79 of mouse PPARg1 (accession number; AAA62110), which also corresponds to amino acids 62-81 of human PPARg1 (CAA62152) or 90-109 of human PPARg2 (AAB04028). This antibody therefore recognizes both human PPARg1 and g2. The characterization of this antibody has been previously confirmed by both immunoblotting and immunohistochemistry (Sato et al. 2004) . The characteristics of polyclonal antibodies for RXRa, RXRb and RXRg have been previously reported by the authors (Sugawara et al. 1995 . Monoclonal antibodies for ERa (ER1D5), progesterone receptor (PR; MAB429), Ki-67 (MIB1), p21 (6B6), p27 (1B4), c-Myc (1-6E10), pS2 (M7184), and cyclin D1 (P2D11F11) were purchased from Immunotech (Marseille, France), Chemicon (Temecula, CA, USA), DAKO (Carpinteria, CA, USA), Pharmingen (San Diego, CA, USA), Novocastra Laboratories (Newcastle, UK), Cambridge Research Biochemical (Cambridge, UK), DAKO and Novocastra Laboratories respectively. Rabbit polyclonal antibodies for ERb (06-629), HER2 (A0485) and cathepsin D (A0561) were obtained from Upstate Biotechnology (Lake Placid, NY, USA), DAKO and DAKO respectively. Goat polyclonal antibody for cyclooxygenase-2 (COX2) (C-20) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Immunohistochemistry
A Histofine Kit (Nichirei, Tokyo, Japan), which employs the streptavidin-biotin amplification method was used in this study. Antigen retrieval for PPARg, ERa,b, PR, RXRa,b,g, HER2, Ki-67, p21, p27 and cyclin D1 immunostaining was performed by heating the slides in an autoclave at 120 C for 5 min in citric acid buffer (2 mM citric acid and 9 mM trisodium citrate dehydrate, pH 6.0), and antigen retrieval for COX2 and pS2 immunostaining was done by heating the slides in a microwave oven for 15 min in the citric acid buffer. Dilutions of primary antibodies used in this study were as follows: PPARg; 1/1500, ERa; 1/50, ERb; 1/50, PR; 1/30; RXRa; 1/4000, RXRb; 1/4000, RXRg; 1/2000, COX2; 1/500, HER2; 1/200, Ki-67; 1/50, p21; 1/250, p27; 1/150, c-Myc 1/600, pS2; 1/30, cyclin D1; 1/40 and cathepsin D; 1/300. The antigenantibody complex was visualized with 3,3 0 -diaminobenzidine solution (1 mM, in 50 mM Tris-HCl buffer (pH 7.6) and 0.006% H 2 O 2 ), and counterstained with hematoxylin. As a negative control, normal rabbit, mouse or goat IgG was used instead of the primary antibodies. For PPARg immunohistochemistry, a preabsorption test was also performed as a negative control.
Scoring of immunoreactivity and statistical analysis
PPARg, ERa,b, PR, RXRa,b,g, Ki-67, p21, p27, c-Myc and cyclin D1 immunoreactivity was detected in the nucleus, and the immunoreactivity was evaluated in more than 1000 carcinoma cells for each case, and subsequently the percentage of immunoreactivity, i.e. labeling index (LI), was determined. Inter-observer differences were less than 5%, and the mean of the three values was obtained. Cases with PPARg, ERa or c-Myc LIs of more than 10% were considered PPARg-, ERa-or c-Myc-positive breast carcinomas in this study, according to a report for ERa by Allred et al. (1998) . For p21 and p27 immunohistochemistry, the cut-off values used were 5 and 50% respectively, according to previous reports (Barbareschi et al. 2000 , Pellikainen et al. 2003 . Immunoreactivity for COX2 and cathepsin D was detected in the cytoplasm, and cases that had more than 10% of positive carcinoma cells were considered positive.
An association between immunoreactivity for PPARg and clinicopathological factors was evaluated using a one-way ANOVA and a Bonferroni test or a cross-table using the chi-square test. Overall and disease-free survival curves were generated according to the Kaplan-Meier method and statistical significance was calculated using the log-rank test. An association between ERa LI and PR or cyclin D1 LI was performed utilizing a correlation coefficient (r) and regression equation. Univariate and multivariate analyses were evaluated by a proportional hazard model (Cox) using PROC PHREG in our SAS software. P values less than 0.05 were considered significant in this study.
Cell line, plasmids and chemicals MCF-7 human breast cancer cell line was cultured in RPMI-1640 (Sigma-Aldrich, St Louis, MO, USA) with 10% fetal bovine serum (FBS) (JRH Biosciences, Lenexa, KS, USA). MCF-7 cells were cultured with phenol red-free RPMI 1640 medium containing 10% dextran-coated charcoal (DCC)-FBS for 3 days before treatment in the experiment. In this study, we used estrogen-responsive reporter plasmids pERE-Luc, containing Xenopus vitellogenin A2 estrogen-responsive element (ERE) (Saji et al. 2001) . The pRL-TK vectors were purchased from Promega (Madison, WI, USA). 15d-PGJ 2 , ciglitazone and PGF 2a were purchased from Biomol Research Laboratories (Butler Pike, PA, USA), and GW1929 and GW9662 were purchased from Sigma-Aldrich.
Luciferase assay
The luciferase assay was performed according to a previous report (Sakamoto et al. 2002) with some modifications. Briefly, 1 mg ptk-ERE-Luc plasmids and 200 ng pRL-TK control plasmids were used to measure the transcriptional activity of endogenous ER. Transient transfections were carried out using TransIT-LT Transfection Reagents (TaKaRa, Tokyo, Japan) in MCF-7 cells, and the luciferase activity of lysates was measured using a Dual-Luciferase Reporter Assay system (Promega) and Luminescencer-PSN (AB-2200) (Atto Co., Tokyo, Japan) after incubation with growth medium with the indicated concentrations of estradiol and/or 15d-PGJ 2 for 24 h. The cells were also treated with the same volume of ethanol (final dilution -0.1%) for 24 h as controls. The transfection efficiency was normalized against Renilla luciferase activity using pRL-TK control plasmids, and the luciferase activity for each sample was evaluated as a ratio (%) compared with that of controls. The statistical analyses were performed using a one-way ANOVA and Bonferroni test.
Immunoblotting
The cell protein was extracted in triple detergent lysis buffer (LK-18) at 4 C. Twenty micrograms of the protein (whole cell extracts) were subjected to SDS-PAGE (10% acrylamide gel). Following SDS-PAGE, proteins were transferred onto Hybond P polyvinylidene difluoride membrane (Amersham Biosciences, Piscataway, NJ, USA). The blots were blocked in 5% non-fat dry skim milk for 1 h at room temperature, and were then incubated with a primary antibody for ERa, p21, p27 or b-actin (Sigma-Aldrich) for 18 h at 4 C. After incubation with anti-mouse IgG horseradish peroxidase (Amersham Biosciences) for 1 h at room temperature, antibody-protein complexes on the blots were detected using ECL-plus western blotting detection reagents (Amersham Biosciences). Immunointensity of Endocrine-Related Cancer (2006) 13 233-250 www.endocrinology-journals.org specific bands was measured by an LAS-1000 imaging system (Fuji Photo Film, Tokyo, Japan), and relative immunointensity of ERa, p21 or p27 was evaluated as a ratio (%) of b-actin immunointensity.
Microarray analysis
In this study, we used a custom-made microarray named EstrArray (InfoGenes, Tsukuba, Japan), which contains 175 estrogen-responsive genes identified in MCF-7 cells (Inoue et al. 2002 , Hayashi et al. 2003 . MCF-7 cells were cultured with phenol red-free RPMI 1640 medium containing 10% DCC-FBS for 3 days, and subsequently treated with estradiol (10 nM) with or without 15d-PGJ 2 (5 mM) for 72 h. The MCF-7 cells used as references were treated with the same volume of ethanol (final dilution -0.1%) for 72 h.
Total RNA was isolated using TRIzol reagent (InVitrogen Life Technologies, Inc., Gaitherburg, MD, USA). Two micrograms of mRNA were reverse-transcribed with Cy3-or Cy5-dUTP (Amersham Biosciences, Bucks, UK) using a SUPER-SCRIPT II Preamplification system (Gibco-BRL, Grand Island, NY, USA). Cy3-and Cy5-labeled cDNA probes were hybridized on the microarray slide for 16 h at 65 C. The fluorescent signals were scanned by a GenePix 4000A (Axon Instruments, Foster City, CA, USA), and the ratio of Cy3 and Cy5 signal intensity of each spot was quantitatively calculated using GenePixPro 5.0 (Axon Instruments). The duplicated sets of values were averaged and normalized by subtracting the average of values for internal genes.
The data from insufficient hybridization (signal areas below 100) were excluded from the analysis. Genes which showed a value of more than 2.0 or less than 0.5 were evaluated as significantly up-regulated or downregulated respectively, in this study.
Real-time PCR
MCF-7 cells were cultured with phenol red-free RPMI 1640 medium containing 10% DCC-FBS for 3 days, and subsequently treated with the indicated concentration of estradiol and/or 15d-PGJ 2 for 72 h. As controls for the experiments, the cells were treated with the same volume of ethanol (final dilution -0.1%) for 72 h. Total RNA was extracted using TRIzol reagent (InVitrogen Life Technologies, Inc.), and a reverse transcription kit (SUPERSCRIPT II Preamplification system (Gibco-BRL) was used in the synthesis of cDNA.
The Light Cycler System (Roche Diagnositics GmbH, Mannheim, Germany) was used to semiquantify the mRNA expression levels by real-time PCR (Dumoulin et al. 2000) . Characteristics of the primer sequences used in this study are summarized in Table 1 (Colombel et al. 1999 , Schonherr et al. 2001 , Vandesompele et al. 2002 , Kao et al. 2003 , Paruthiyil et al. 2004 , Yoshida et al. 2004 . Settings for the PCR thermal profile were: initial denaturation at 95 C for 1 min followed by 40 amplification cycles of 95 C for 1 s, annealing at 59 C (PR), 60 C (pS2, PDZ domain-containing protein (PDZK1), cathepsin D, selenium-binding protein 1 (SELENBP1), tumor protein D52-like 1 (TPD52L1), insulin-like growth factor-binding protein-5 (IGFBP-5), PDZ domaincontaining-protein (PDZK1), and p21), 64 C (cyclin D1, and tumor-associated antigen L6 (TAL6)), 66 C (solute carrier family 7, member 5 (SLC7A5), and p27), or 68 C (ribosomal protein L 13a (RPL13A)) for 15 s, and elongation at 72 C for 15 s. To verify amplification of the correct sequences, PCR products were purified and subjected to direct sequencing. Negative control experiments lacked cDNA substrate to check for the possibility of exogenous contaminant DNA. The mRNA levels were summarized as a ratio of RPL13A, and subsequently evaluated as a ratio (%) compared with that of controls. The statistical analyses were performed using a one-way ANOVA and Bonferroni test.
Cell proliferation assay and apoptosis analysis
The status of cell proliferation of MCF-7 cells was measured using a WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2-H-tetrazolium, monosodium salt) method (Cell Counting Kit-8; Dojindo Inc., Kumamoto, Japan)) (Isobe et al. 1999) . We also examined apoptosis status of MCF-7 cells using an apoptosis screening kit (Wako, Osaka, Japan), which employed a modified TdTmediated dUTP nick-end labeling (TUNEL) method (Gavrieli et al. 1992) . Optical densities (OD = 450 nM for cell proliferation assay, and OD = 490 nM for 
Results
Immunohistochemistry for PPARg in breast carcinoma tissues
Immunoreactivity for PPARg was detected in the nuclei of invasive ductal carcinoma cells ( Fig. 1A and B). A mean value of PPARg LI in 238 breast carcinoma cases examined was 15% (range 0-74%), and the number of PPARg-positive breast carcinomas (i.e. PPARg LIi10%) was 99 out of 238 cases (42%).
Immunoreactivity of PPARg was also detected in epithelia of morphologically normal mammary glands ( Fig. 1C ), and adipocytes ( Fig. 1D ).
Associations between PPARg immunoreactivity and clinicopathological parameters in 238 breast carcinomas were summarized in Table 2 . PPARg immunoreactivity was significantly associated with ERa status (P = 0.0003), ERa LI (P<0.0001), ERb LI (P = 0.0255), PR LI (P = 0.0012), RXRa LI (P = 0.0365), RXRb LI (P<0.0001), RXRg LI (P = 0.0005), p21 immunoreactivity (P = 0.0057) or p27 immunoreactivity (P = 0.0019). PPARg immunoreactivity was negatively correlated with histological grade (P = 0.0035) or COX2 immunoreactivity (P = 0.0178). No significant association was detected between PPARa immunoreactivity and other clinicopathological parameters examined, including patient age, menopausal status, clinical stage, tumor size, lymph node status, HER2 status, Ki-67 LI, and c-Myc immunoreactivity in this study. The association between PPARg immunoreactivity and RXRb LI, RXRg LI, COX2 immunoreactivity, p21 immunoreactivity or p27 immunoreactivity was significant regardless of ERa status of these cases (Table 3) . PPARg immunoreactivity was positively correlated with RXRa LI (P = 0.0469) and inversely with lymph node status (P = 0.0303) or Ki-67 LI (P = 0.0485) only in the ERa-positive group.
Influence of PPARg immunoreactivity on association between ERa and estrogenresponsive genes in breast cancer tissues pS2, cyclin D1, PR and cathepsin D are all well recognized as estrogen-responsive genes in human breast cancers. As shown in Table 4 , a significant positive association was detected between ERa LI and the status of these immunoreactivity in the 238 breast cancer tissues examined (P<0.0001), which is in good agreement with previous immunohistochemical studies (Horwitz & McGuire 1978 , Barbareschi et al. 1997 , Gillesby & Zacharewski 1999 , Ioachim et al. 2003 . When the breast cancers were classified into two groups according to their PPARg status, no significant association was detected between ERa LI and pS2 (P = 0.3785) or cyclin D1 LI (P = 0.1978) in PPARgpositive breast carcinomas, although significant association (P<0.0001 for pS2, and P = 0.0018 for cyclin D1) was detected in PPARg-negative breast carcinomas. On the other hand, ERa LI was significantly associated with PR LI (P = 0.0008 in PPARg-positive cases, and P<0.0001 in PPARgnegative cases) or cathepsin D (P = 0.0006 in PPARg-positive cases, and P = 0.0003 in PPARgnegative cases) regardless of the PPARg status in the breast carcinoma cases examined.
Correlation between PPARg immunoreactivity and clinical outcome of the patients
No significant association was detected between PPARg immunoreactivity and a risk of recurrence (P = 0.8715) ( Fig. 2A) . PPARg immunoreactivity was significantly associated with a better clinical outcome of the 238 breast cancer patients (P = 0.0257) (Fig. 2B ). This significant association was detected in the ERa-positive group (P = 0.0057) (Fig. 2C ), but not in the ERa-negative group (P = 0.6405) (Fig. 2D ). The significant correlation between PPARg immunoreactivity and overall survival of ERa-positive breast cancer patients was not influenced by tamoxifen therapy after the surgery ( Fig. 2E and F) . Utilizing a univariate analysis (Table 5) , lymph node status (P<0.0001), histological grade (P<0.0001), tumor size (P = 0.0002), HER2 status (P = 0.0029), c-Myc immunoreactivity (P = 0.0066), and PPARg immunoreactivity (P = 0.0287) turned out to be significant prognostic factors for overall survival in this study. Multivariate analysis revealed that only lymph node status (P<0.0001) and c-Myc immunoreactivity (P = 0.0024) were independent prognostic factors with a relative risk over 1.0 (Table 5) . When we examined a univariate analysis in the ERa-positive breast cancer patients (n = 174), lymph node status (P<0.0001), histological grade (P<0.0001), tumor size (P<0.0001), HER2 status (P = 0.0008), PPARg immunoreactivity (P = 0.0076) and c-Myc immunoreactivity (P = 0.0252) were demonstrated as significant prognostic factors for overall survival (Table 6) . A multivariate analysis revealed that lymph node status (P<0.0001) and PPARg immunoreactivity (P = 0.0372) were independent prognostic factors with relative risks over 1.0. Figure 2 Disease-free (A) and overall (B-F) survival of 238 patients with breast carcinoma according to PPARg immunoreactivity (Kaplan-Meier method). PPARg immunoreactivity was not correlated with a risk of recurrence (P = 0.8715 in log-rank test) (A), but significantly associated with an improved overall survival (P = 0.0257 in log-rank test) (B). The significant association was detected in the ERa-positive group (n = 174; P = 0.0057 in log-rank test) (C), but not in the ERa-negative cases (n = 64; P = 0.6405 in log-rank test) (D). PPARg immunoreactivity was significantly associated with an improved prognosis regardless of tamoxifen therapy after surgery in the ERa-positive breast cancer patients (E, F). P values less than 0.05 are in boldface.
interaction of these two nuclear receptors in human breast carcinoma cells. Previously, Keller et al. (1995) reported that PPARa/RXRb heterodimer can bind to ERE and possibly modulate the ER-signaling pathway, but this has not been examined in breast cancers.
In order to examine this hypothesis, we used MCF-7 breast cancer cells in the following in vitro experiments, because MCF-7 cells were associated with expression of ERa, PPARg, and RXRa, b, g (data not shown). When MCF-7 cells were transiently transfected with ptk-ERE-Luc plasmids and treated with 10 nM estradiol, the luciferase activity of the cells was 17-fold increased compared with their basal level (Fig. 3A) . PPARg activator 15d-PGJ 2 significantly inhibited ERE-dependent transactivation by estradiol in a dose-dependent manner, and the luciferase activity of MCF-7 cells treated with 10 nM estradiol and 5 mM 15d-PGJ 2 was decreased to 53% of that treated with 10 nM estradiol alone (P<0.001). 15d-PGJ 2 (5 mM) alone did not significantly change the luciferase activity compared with their basal level (P = 0.8837). 15d-PGJ 2 , however, did not significantly inhibit the ERE-dependent transactivation by estradiol, when these cells were treated with a potent PPARg antagonist GW9662 (Leesnitzer et al. 2002) .
The ERE-dependent transactivation by estradiol was also inhibited by other PPARg agonists such as GW1929 and ciglitazone, in a dose-dependent manner (P<0.001, on addition of 5 mM GW1929 or ciglitazone), but was not altered by treatment with PGF 2a , which does not activate PPARg (Kliewer et al. 1995) (Fig. 3B) . Results of immunoblotting analysis revealed that relative immunointensity of ERa was not significantly (P = 0.7749) altered by the treatment with 15d-PGJ 2 in MCF-7 cells (Fig. 3C) . 
Effects of 15d-PGJ 2 on estrogen-mediated transcription in MCF-7 cells in microarray analysis
We further examined the effects of 15d-PGJ 2 on estrogen-mediated transcription in MCF-7 cells using a custom-made microarray. Significant alterations of mRNA expression by estradiol treatment (10 nM for 72 h) were detected in 49 genes in this study, and these genes were classified into the following four groups (Table 7) : Group A; mRNA expression was significantly up-regulated by estradiol, but the significance vanished on addition of 15d-PGJ 2 (5 mM) (nine genes; Table 8 ), Group B; mRNA expression was significantly up-regulated by estradiol with or without 15d-PGJ 2 (23 genes; Table 9 ), Group C; mRNA expression was significantly down-regulated by estradiol, but the significance vanished on addition of 15d-PGJ 2 (seven genes; Table 10 ), and Group D; mRNA expression was significantly down-regulated by estradiol with or without 15d-PGJ 2 (ten genes; Table 11 ).
Effects of 15d-PGJ 2 on estrogen-mediated transcription in MCF-7 cells using real-time PCR analysis
In order to confirm the results from microarray analysis, we performed real-time PCR analyses for the representative 11 genes in MCF-7 cells (Fig. 4A-K ). A custom-made microarray (EstrArray; InfoGenes, Co. Ltd, Tsukuba, Japan), which contains 175 estrogen-responsive genes (Inoue et al. 2002 , Hayashi et al. 2003 , was used in this study. MCF-7 cells were treated with estradiol (10 nM) with or without 15d-PGJ 2 (5 mM) for 72 h. Genes showing the value of more than 2.0-or less than 0.5-fold compared with the control (treated without estradiol or 15d-PGJ 2 for 72 h) were regarded as significantly regulated.
mRNA expression of pS2 (Fig. 4A) , PDZK1 (Fig. 4B ) cyclin D1 (Fig. 4C ) and IGFBP-4 (Fig. 4D ), which were tentatively classified into Group A in microarray analysis as above, was significantly (P<0.001) increased by estradiol treatment (10 nM, for 72 h) compared with the control (neither estradiol nor 15d-PGJ 2 ), but not by treatment with estradiol (10 nM) with 15d-PGJ 2 (5 mM). mRNA expression of SLC7A5 (Fig. 4E) , TPD52L1 (Fig. 4F) , PR (Fig. 4G) , and cathepsin D (Fig. 4H) in Group B was, however, significantly upregulated by the treatment with estradiol with or without 15d-PGJ 2 (1 or 5 mM). Estradiol-mediated mRNA expression of PR was also demonstrated to be inhibited by addition of 15d-PGJ 2 in a dose-dependent manner (P<0.01, between estradiol alone and estradiol with 15d-PGJ 2 (5 mM)). The mRNA level of TAL6 in Group C (Fig. 4I ) was significantly lower (P<0.001) in estradiol alone than that in the control group, but was not significantly different under treatment with estradiol with 15d-PGJ 2 (5 mM). mRNA expression of IGFBP-5 (Fig. 4J ) and SELENBP1 (Fig. 4K ) in Group D was significantly down-regulated by the treatment with estradiol (10 nM) with or without 15d-PGJ 2 (1 or 5 mM). mRNA expression in these 11 genes was not significantly altered by treatment with 15d-PGJ 2 (5 mM) alone in this study. Values are presented as fold change compared with controls. Boldface: mRNA expressions were examined by real-time PCR analysis (Fig. 4) . Values are presented as fold change compared with controls. Boldface: mRNA expressions were examined by real-time PCR analysis (Fig. 4) . Values are presented as fold change compared with controls. Boldface: mRNA expressions were examined by real-time PCR analysis (Fig. 4) . Values are presented as fold change compared with controls. Boldface: mRNA expressions were examined by real-time PCR analysis (Fig. 4) .
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Effects of 15d-PGJ 2 on estrogen-mediated proliferation of MCF-7 cells
The number of MCF-7 cells was significantly increased after the treatment with estradiol (10 nM) in a timedependent manner, and was 1.4-fold higher than the basal level (control: no treatment with estradiol or 15d-PGJ 2 ) at 5 days after the treatment (Fig. 5A) . The estrogen-mediated proliferation of MCF-7 cells was significantly inhibited by addition of 5 mM 15d-PGJ 2 (P<0.05 and P<0.001 for 3 and 5 days respectively). The apoptosis index of MCF-7 cells was not significantly altered under the same treatments for 3 days (Fig. 5B ). The treatment with 5 mM 15d-PGJ 2 We also examined effects of 15d-PGJ 2 on the expression of p21 and p27 in MCF-7 cells. Results of real-time PCR analyses demonstrated significant (P<0.001) stimulation of p21 mRNA by 15d-PGJ 2 (5 mM for 3 days) (Fig. 5C) . In immunoblotting analyses, relative immunointensities of p21 and p27 were significantly (P<0.05) increased by the treatment with 15d-PGJ 2 in a dose-dependent manner (Fig. 5D ).
Discussion
In our present study, PPARg immunoreactivity was detected in carcinoma cells in 99 out of 238 human Endocrine-Related Cancer (2006) 13 233-250 www.endocrinology-journals.org breast carcinomas (42%), and was significantly associated with the histological grade or ERa status of the cases. Expression of PPARg has been previously reported in breast cancer cases by several groups (Mueller et al. 1998 , Jiang et al. 2003 , Watkins et al. 2004 . Mueller et al. (1998) reported that ligandactivated PPARg in cultured breast cancer cells resulted in extensive lipid accumulation, and transformed the breast epithelial gene expression to a more differentiated and less-malignant state. In addition, both Jiang et al. (2003) and Watkins et al. (2004) reported that PPARg expression was significantly lower in breast cancer tissues than in normal tissues, suggesting that PPARg has a possible protective role against development of breast cancers (Jiang et al. 2003 , Koeffler 2003 . Results of our present study are generally consistent with these previously reported findings, and PPARg may be mainly expressed in well-differentiated breast carcinomas with hormonal regulatory mechanisms maintained.
It then becomes important to know whether PPARg is colocalized with RXRs and its natural ligands or not in breast cancers, because these factors play essential roles in activation of PPARg function. PPARg immunoreactivity was significantly associated with all the subtypes of RXR. RXRa and RXRb are known to be major subtypes of RXR in breast cancer tissues , and PPARg/RXRa heterodimer was reported to be biologically active in human breast cancer cells (Crowe & Chandraratna 2004) . Therefore, PPARg is mainly expressed in RXR-overexpressing breast cancer tissues, and possibly heterodimerizes with RXRa and/or RXRb in breast cancer cells. Previously, Badawi & Badr (2003) reported that concentration of 15d-PGJ 2 , which is considered a natural ligand of PPARg, was inversely correlated with mRNA expression of COX2 or concentration of PGE 2 , and was marginally associated (P = 0.081) with PPARg mRNA levels in breast cancer tissues. In addition, estrogen is known to influence PG synthesis in estrogen target tissues (Ham et al. 1975) . Ma et al. (1998a) reported that estrogen induced enzymatic conversion of PGD 2 and the metabolites of PGD 2 potently activated PPARg, although estrogen did not directly induce the mRNA expression of PPARg (Ma et al. 1998b) . In our present study, PPARg immunoreactivity was inversely associated with COX2 immunoreactivity and positively associated with ERa, although we could not examine the tissue concentrations of natural PPARg ligands in breast cancer tissues. These data suggest that PPARg is biologically activated in human breast cancer tissues.
Estrogens are well-known to contribute immensely to the development of hormone-dependent breast carcinomas, and biological estrogenic actions are mainly mediated by ERa (Korach 1994) . Estrogens stimulate the transactivation of activation function 2 domain of ERa in a ligand-dependent manner (Kumar et al. 1987) , and subsequently ERs activate transcription of various target genes by direct DNA interaction through EREs or by tethering to other transcription factors (Tsai & O'Malley 1994 , Acconcia & Marino 2003 . Previously, Keller et al. (1995) demonstrated that PPARa/RXRb heterodimer could bind to ERE using the artificial promoter context. In this report, PPARa/RXRb strongly bound with EREs of pS2 and vitellogenin A2 (vitA2) genes, but did not induce these ERE-dependent transactivations (Keller et al. 1995) . The binding affinity between PPARa/RXRb and ERE of very-low-density apolipoprotein II gene was, however, very low, despite containing the same ERE consensus sequence as vitA2. In our study, ligandmediated PPARg activation significantly inhibited estrogen-mediated ERE transactivation in MCF-7 cells. These data are in good agreement with the report by Keller et al. (1995) , and suggest that PPARg suppresses the estrogen-signaling pathway through inhibition of the binding of ERs with the target genes in breast cancer cells. In our microarray analysis, inhibition of estrogen-mediated mRNA expression by PPARg was detected in 33% of estrogen-responsive genes, including ERE-containing genes such as pS2 (Stack et al. 1988 ) and early growth response 3 (Bourdeau et al. 2004 ). However, 15d-PGJ 2 did not significantly regulate the estrogen-mediated transactivation of a proportion of ERE-containing genes, such as SLC7A5 (Bourdeau et al. 2004) , cathepsin D (Wang et al. 1997) , retinoblastoma-binding protein 8 (Bourdeau et al. 2004) , and Fos-like antigen 2 (Bourdeau et al. 2004) . On the other hand, 15d-PGJ 2 inhibited the estrogen-mediated expression of cyclin D1 and IGFBP-4 (Group A), in which functional ERE has not been identified and indirect gene regulation by ER is suggested (Qin et al. 1999 , Acconcia & Marino 2003 , O'Lone et al. 2004 . Therefore, inhibition of PPARg in estrogen-mediated transactivation is considered to vary among the target genes, and may influence not only ERE-containing genes but also some genes which are induced by an interaction between ER and other DNA-binding transcription factors.
In our immunohistochemical analysis (Table 4) , significant associations were detected between ERa and estrogen-responsive genes, such as pS2, cyclin D1, PR and cathepsin D, as reported previously (Barbareschi et al. 1997 , Gillesby & Zacharewski 1999 , Ioachim et al. 2003 . However, the significant association between ERa and pS2 or cyclin D1 was not detected in the group of PPARg-positive breast cancers, while correlation between ERa and PR or cathepsin D was not influenced by PPARg status in those breast cancer patients examined. These data are in good agreement with our results of microarray and real-time PCR analyses. Recently, Qin et al. (2003) reported that PPARg agonists induced proteasomedependent degradation of cyclin D1, which may be partly involved in the present immunohistochemical results of cyclin D1.
In this study, PPARg immunoreactivity was correlated with immunoreactivity of p21 and p27 in breast carcinoma tissues, and expression of p21 and p27 was significantly induced by 15d-PGJ 2 at mRNA and/or protein levels in MCF-7 cells. Previous studies demonstrated that PPARg ligands induced cyclindependent kinase inhibitors such as p21 and p27 in various types of cancer cells (Chung et al. 2002 , Han et al. 2004 , Motomura et al. 2004 , and Lapillonne et al. (2003) reported the induction of p21 by a novel synthetic ligand for PPARg (2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) in breast carcinoma cells. A potential conserved consensus PPRE was detected in the promoter region of p21 gene (Lapillonne et al. 2003 , Qin et al. 2003 , and Motomura et al. (2004) have reported that accumulation of p27 by ligandactivated PPARg was caused by induction of ubiquitination of p27 and reduction of degradation activity of p27 by proteasomes in hepatocellular carcinoma cells. Results of our present study are consistent with these previous reports, and suggest that PPARg regulates the expression of p21 and p27 in breast cancer tissues.
PPARg immunoreactivity was demonstrated as an independent improved prognostic factor for overall survival in ERa-positive breast carcinoma patients in our study, although it may not be as robust as lymph node status, a well-established diagnostic modality (Dowlatshahi et al. 1997) . In addition, 15d-PGJ 2 significantly inhibited the estrogen-mediated proliferation in MCF-7 cells. Recently, Jiang et al. (2003) reported that mRNA levels of PPARg in patients with local recurrence or those who died of breast cancer were significantly lower than those who remained disease free, which is generally consistent with our immunohistochemical results. An antiproliferative effect of PPARg is considered to be, at least in part, due to overexpression of p21 and/or p27 in carcinoma cells, but this mechanism still remains largely unknown. Immunoreactivities of p21 and p27 are not necessarily associated with improved clinical outcomes of breast cancer patients (Barbareschi et al. 2000 , Pellikainen et al. 2003 , which is consistent with the findings in our present study (Table 5) . PPARg modulates estrogenic actions in breast carcinoma cells, through the suppression of a part of estrogen-mediated transactivation as described above, which may be also involved in an improved prognosis in breast carcinoma patients positive for PPARg and ERa. Further examinations are required to clarify detailed functions of PPARg as a modulator of estrogenic actions in breast carcinoma tissues.
In summary, PPARg immunoreactivity was detected in carcinoma cells in 42% of breast cancer tissues. PPARg immunoreactivity was positively associated with ERs, PR, RXRs, p21, or p27, and negatively correlated with histological grade or COX2. Moreover, PPARg immunoreactivity was a better independent prognostic factor in ERa-positive breast carcinoma patients. Ligand-mediated PPARg activation caused the suppression of a portion of estrogen-mediated transactivation or inhibition of estrogen-mediated proliferation in MCF-7 cells. These findings suggest that PPARg is mainly expressed in well-differentiated and ER-positive breast cancers, and in part, plays a role as a modulator of estrogenic actions.
